Efficacy and Safety of Once Daily Gliclazide (20 mg/day) Compared with Nateglinide

Miwa, Shinnya; Watada, Hirotaka; Ohmura, Chie; Tanaka, Yasushi; Kawamori, Ryuzo

doi:10.1507/endocrj.51.393

Cited by 20 publications

(11 citation statements)

References 16 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, weight gain and edema were almost negligible in our patients treated with 7.5-mg pioglitazone, suggesting the safety of 7.5-mg pioglitazone. Additionally, consistent with previous reports [2-6, 10, 14, 15], there were no cases of drug-induced hepatotoxicity or hypoglycemia in either group in our study, while hypoglycemia is a common adverse event in other glucose-lowering agents [26].…”

Section: Discussionsupporting

confidence: 93%

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

et al. 2006

View full text Add to dashboard Cite

Abstract. It is well known that pioglitazone, a potent thiazolidinedione, improves metabolic control. However, weight gain or peripheral edema may be of major clinical concern when using this agent. The purpose of our study was to prospectively evaluate the effects of low-dose pioglitazone (7.5 mg/day) on metabolic control, weight gain and the incidence of edema compared with a standard dose of pioglitazone (15.0 mg/day) in patients with type 2 diabetes mellitus (T2DM). Ninety-five Japanese female patients (mean age 58.4 ± 10.4 years) with newly diagnosed T2DM were selected for this study. They were randomly divided into the following 2 groups according to therapy regimens, and examined every month for 6 months after diagnosis. Group A consisted of 54 patients treated with low-dose pioglitazone orally; Group B, the control-group, consisted of 41 patients treated with standard-dose pioglitazone orally. The incidence of peripheral edema was significantly much lower in group A (2/54) than in group B (11/41) (p = 0.0014). In addition, % change of body weight during the 6-month treatment in group A was significantly less than that in group B (p<0.0001). On the other hand, the % change of biochemical parameters including HbA1c did not differ significantly between group A and group B, although glucose and lipid control significantly improved from baseline in both groups. Our results demonstrate the safety and efficacy of low-dose pioglitazone, suggesting that it could be another good choice of treatment for Japanese women with T2DM.

show abstract

Section: Discussionsupporting

confidence: 93%

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

et al. 2006

View full text Add to dashboard Cite

show abstract

“…We previously described that nateglinide improved glycemic response after oral glucose load in obese individuals with impaired glucose tolerance or early type 2 diabetes by improvement of early phase insulin secretion without increasing the total amount of insulin (i.e., area under the curve) [15,16]. While we compared the effects of a small dose of gliclazide (20 mg) with nateglinide (270 mg), the hypoglycemic effects of glicalzide are stronger though it elicited more frequent hypoglycemic episodes [17]. Even when administered at a single high dose (3420 mg), the hypoglycemic effect of nateglinide appeared immediately and did not last more than 6 hours [18].…”

Section: Discussionmentioning

confidence: 97%

Therapeutic Efficacy of Mitiglinide Combined with Once Daily Insulin Glargine after Switching from Multiple Daily Insulin Regimen of Aspart Insulin and Glargine in Patients with Type 2 Diabetes Mellitus

et al. 2006

Self Cite

View full text Add to dashboard Cite

Abstract. Mitiglinide is novel class of rapid-acting insulin secretagogues, which have been widely used alone or in combination with other oral hypoglycemic drugs to improve postprandial hyperglycemia in early type 2 diabetes. While mitiglinide enhances postprandial requirement of insulin, the efficacy of mitiglinide combined with insulin has yet to be established. We investigated the efficacy of mitiglinide combined with insulin glargine, the first soluble insulin analog that has a flat and prolonged effect. After control with the intensive regimen (daily aspart insulin and glargine), 30 inpatients with type 2 diabetes were switched to premeal mitiglinide combined with once daily insulin glargine (mitiglinide regimen), and daily profiles of blood glucose level were compared under each regimen. Fifteen patients showed similar control of hyperglycemia with mitiglinide regimen and intensive insulin regimen, assessed by M value (<32), while the remaining 15 showed worsening under the mitiglinide regimen. The patients who were well controlled with mitiglinide regimen were significantly younger (51.9 ± 16.0 years, p<0.005) and heavier (body mass index: 25.7 ± 3.3 kg/m 2 , p<0.05) than those who were not (67.9 ± 8.7 and 23.0 ± 3.1, respectively). Moreover, insulin doses of aspart per body weight were significantly fewer in effective group than in ineffective group. Duration of diabetes was shorter in the effective group, albeit insignificantly. Previous treatment before starting intensive insulin regimen, such as insulin and sulfonylurea, was not different between the two groups. Our results suggest that mitiglinide plus insulin glargine combination therapy is useful for lowering both fasting and postprandial hyperglycemia in a subpopulation of type 2 diabetes. The long-term effects of such treatment need to be established in future studies.

show abstract

“…MDA-LDL was measured by an enzyme-linked immunosorbent assay (ELISA) method based on the principle previously reported by Kotani et al [14]. To estimate the extent of cholesterol peroxidation, the level of 3,5,7-cholestatriene in erythrocyte membranes was measured using gas chromatography-mass spectrometry, as described previously [11,15].…”

Section: Assaysmentioning

confidence: 99%

Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients

et al. 2005

Self Cite

View full text Add to dashboard Cite

Abstract. An open-label prospective cross-over trial was performed to evaluate the antioxidative effect of fluvastatin in Japanese type 2 diabetics with hyperlipidemia. The study subjects were 10 patients who were on pravastatin (10 mg/day) or simvastatin (5 mg/day). After at least 12 weeks of continuous pravastatin or simvastatin therapy, the drugs were washed out for 12 weeks and replaced with fluvastatin (30 mg/day), then the treatment was continued for another 12 weeks. Total cholesterol and LDL cholesterol were efficiently and comparably reduced by all three statin agents. There were no differences in serum parameters of oxidative stress such as malondialdehyde-modified low-density lipoprotein, thiobarbituric acid-reactive substances, and 8-iso-prostaglandin F2a between pravastatin/simvastatin and fluvastatin. However, fluvastatin, but not pravastatin/simvastatin, significantly reduced 3,5,7-cholestatriene in erythrocyte membrane, representing the extent of membrane cholesterol peroxidation. Our data demonstrated that fluvastatin has a unique anti-oxidative effect in patients with type 2 diabetes and hyperlipidemia, compared with other statins.

show abstract

Efficacy and Safety of Once Daily Gliclazide (20 mg/day) Compared with Nateglinide

Cited by 20 publications

References 16 publications

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

Safety and Efficacy of Low-dose Pioglitazone (7.5 mg/day) vs. Standard-dose Pioglitazone (15 mg/day) in Japanese Women with Type 2 Diabetes Mellitus

Therapeutic Efficacy of Mitiglinide Combined with Once Daily Insulin Glargine after Switching from Multiple Daily Insulin Regimen of Aspart Insulin and Glargine in Patients with Type 2 Diabetes Mellitus

Anti-oxidative Effect of Fluvastatin in Hyperlipidemic Type 2 Diabetic Patients

Contact Info

Product

Resources

About